LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Aurinia Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

12.09 -0.9

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.95

Max

12.21

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.8M

22M

Pardavimai

7.5M

70M

P/E

Sektoriaus vid.

28.221

35.724

Pelno marža

30.729

Darbuotojai

130

EBITDA

6.3M

28M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

-1.72% downside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

396M

1.6B

Ankstesnė atidarymo kaina

12.99

Ankstesnė uždarymo kaina

12.09

Naujienos nuotaikos

By Acuity

50%

50%

172 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-27 22:51; UTC

Uždarbis

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Rev $4.01B

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Adj EPS $1.84

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H EPS $1.82

2025-08-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025-08-27 23:39; UTC

Uždarbis

Correction to Nvidia Earnings Article -- WSJ

2025-08-27 22:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-27 22:59; UTC

Rinkos pokalbiai

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025-08-27 22:58; UTC

Uždarbis

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025-08-27 22:57; UTC

Uždarbis

South32 FY Free Cash Flow $192 Million

2025-08-27 22:56; UTC

Uždarbis

South32 FY Total Capital Expenditure $1.35 Billion

2025-08-27 22:56; UTC

Uždarbis

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025-08-27 22:55; UTC

Uždarbis

South32 Net Cash $123 Million at June 30

2025-08-27 22:54; UTC

Uždarbis

South32: Focused on Maintaining Strong Operating Momentum

2025-08-27 22:53; UTC

Uždarbis

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025-08-27 22:53; UTC

Uždarbis

South32 Extends Capital Management Program for 12 Months

2025-08-27 22:52; UTC

Uždarbis

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025-08-27 22:50; UTC

Uždarbis

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025-08-27 22:50; UTC

Uždarbis

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025-08-27 22:45; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025-08-27 22:43; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025-08-27 22:43; UTC

Uždarbis

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources Net Debt $123 Million at June 30

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources FY Underlying Ebitda $527.7 Million

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-1.72% į apačią

12 mėnesių prognozė

Vidutinis 12 USD  -1.72%

Aukščiausias 17 USD

Žemiausias 9 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.1 / 8.21Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

172 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.